Regulation
FDA approves Guardant Health’s next-generation liquid biopsy panel
The FDA approved Guardant Health's Guardant360 Liquid, a next-generation liquid biopsy panel that expands genomic assessment to a 100-fold wider footprint compared to its predecessor, intended to support cancer treatment decisions.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network